MétaCan
Menu
Back to cohort

Abstract B054: Intratumoral injection with stimulator of interferon genes (STING) agonist increases T- and B-cell infiltrates in canine osteosarcoma

2024· article· en· W4402266827 on OpenAlexaboutno aff
Michèle Doucet, Stephanie Glavaris, Maggie Phillips, Emily Kulp, Sarah E. Powers, Cory Brayton, Dara L. Kraitchman, Brian H. Ladle

Bibliographic record

VenueCancer Research · 2024
Typearticle
Languageen
FieldImmunology and Microbiology
Topicinterferon and immune responses
Canadian institutionsnot available
Fundersnot available
KeywordsStimulator of interferon genesOsteosarcomaStingAgonistMedicineCancer researchInterferonInternal medicineImmunologyReceptorInnate immune system

Abstract

fetched live from OpenAlex

Abstract We desperately need novel treatment approaches for osteosarcoma beyond cytotoxic chemotherapy and surgery. Our group has an ongoing NIH-funded clinical trial treating canine osteosarcoma with neoadjuvant intratumoral delivery of a stimulator of interferon genes (STING) agonist, cryotherapy, or combined cryotherapy with intratumoral STING agonist injection. Here we report the analysis of 10 dogs treated with neoadjuvant STING agonist alone. Dogs with confirmed localized osteosarcoma were treated under image guidance with intratumoral injection of 100 micrograms of the STING agonist ADU-S100 or R229 (enantiomer of ADU-S100) on days 1 and 8 prior to planned limb amputation on day 15. After recovery from amputation, dogs received standard of care treatment with adjuvant carboplatin per their treating oncologist. We obtained the amputated limb for complete analysis of the treated tumor and peripheral blood samples. Dogs were followed every 3 months with scans and relapse and survival data was captured. We analyzed resected tumors by immunohistochemistry to quantify T cell (CD3+), myeloid cell (IBA1+), and B-cell (CD20+) density comparing areas where the STING agonist was injected to pre-treatment biopsy samples and/or areas of the tumor distant to the injection sites. Cell density was quantified using HALO imaging-analysis software. Tumor areas with immune infiltrates were further characterized by nanoString gene expression profiling and bulk RNA-sequencing. Both treated and untreated areas of every tumor have significant IBA1+ myeloid cell infiltrates. Comparing STING-treated versus untreated areas, 80% of tumors showed >2 fold induction of CD3+ T cell density in STING treated areas (range 4.1-21 fold), and the ratio of T cells : myeloid cells was increased (P=0.004). CD20+ B-cell density also increased by an average of 10.4-fold (range 1.8-44.3-fold). Gene expression analysis indicates predominant effector CD8+ T cell populations, NK cells, activated B cells, and increased effector cell cytokines. We also observed increased regulatory/suppressive pathways such as IDO1, PD1, and TIM3. STING agonist injection increased activated T- and B-cell infiltrates in treated canine osteosarcomas suggesting augmented adaptive immune system activation against the tumor. Compensatory regulatory pathways also increased indicating the potential to further augment immune activation targeting these pathways. Citation Format: Michele Doucet, Stephanie Glavaris, Maggie Phillips, Emily Kulp, Sarah Powers, Kathy Gabrielson, Cory Brayton, Dara Kraitchman, Brian H. Ladle. Intratumoral injection with stimulator of interferon genes (STING) agonist increases T- and B-cell infiltrates in canine osteosarcoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pediatric Cancer Research; 2024 Sep 5-8; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl):Abstract nr B054.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.339
Teacher spread0.307 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicinterferon and immune responsesFrench-language works237,207